Berry Genomics is a technology company.
Berry Genomics has raised $23.0M across 2 funding rounds.
Berry Genomics has raised $23.0M in total across 2 funding rounds.
Berry Genomics has raised $23.0M in total across 2 funding rounds.
Berry Genomics's investors include Qiming Venture Partners.
Berry Genomics is a leading Chinese clinical genomics company specializing in genetic testing services using high-throughput sequencing technologies, including second-generation (short-read) and third-generation (long-read, HiFi) sequencing.[1][2][3] It provides non-invasive solutions for reproductive health, genetic disease screening, tumor testing, and early cancer detection, serving over 2,000 hospitals and institutions across China with products like NIPT (non-invasive prenatal testing), CNV-Seq, whole exome sequencing, and targeted HiFi long-read assays for single-gene disorders.[2][3] The company has delivered over 500 million patient tests cumulatively, focusing on transforming genetic technologies into clinical applications through R&D, certified labs in seven locations, and AI-empowered tools like GENOisi for data management and interpretation.[1][2][3]
Founded in May 2010 and listed on the A-share main board in 2017, Berry Genomics pioneered China's first NGS-based NIPT test that year, marking its entry into reproductive genetics.[1][2] Headquartered in Beijing, it rapidly expanded by building a comprehensive system for R&D, production, marketing, and customer service aligned with international standards, while establishing seven certified clinical labs in major cities including Shanghai, Chengdu, and Hong Kong.[1][2] Early traction came from commercializing short-read assays like NIPT, CMA, WES, and WGS from 2011-2017; pivotal shifts occurred post-2017 with adoption of long-read sequencing (Sequel, Sequel II, Revio, Vega), enabling over 400,000 HiFi tests for complex single-gene disorders like thalassemia, SMA, and hemophilia by 2023.[3][5]
Berry Genomics rides the global wave of precision medicine and genomic sequencing democratization, particularly in Asia's massive population driving demand for scalable, affordable genetic screening amid rising birth defect awareness and cancer burdens.[2][3] Its timing aligns with China's push for localized biotech self-reliance, enabling rapid clinical adoption of imported tech like PacBio's long-read systems while building domestic databases and AI pipelines—critical as short-read limitations hinder single-gene diagnoses.[3][5] Market forces like expanding NGS reimbursement, aging demographics, and gene therapy integration favor its model; it influences China's ecosystem by powering 500 million+ tests, fostering hospital partnerships, and pioneering large-scale long-read clinical use, setting standards for perinatal screening and oncology.[1][2][4]
Berry Genomics is poised to dominate China's clinical genomics with expansions into broader panels, PGT (preimplantation genetic testing), consumer genomics, and gene therapy investments via subsidiaries like Xcelom.[2][5] Trends like AI integration, third-gen sequencing scalability, and multi-omics will accelerate its growth, potentially capturing more oncology and rare disease markets as HiFi assays prove cost-effective at scale.[3] Its influence may evolve from testing leader to full-stack genomic platform provider, reshaping public health outcomes in birth defect prevention and early detection—echoing its founding mission to commercialize genetics for clinical impact.[1][2]
Berry Genomics has raised $23.0M across 2 funding rounds. Most recently, it raised $8.0M Venture Round in March 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2017 | $8.0M Venture Round | Qiming Venture Partners | |
| Apr 1, 2013 | $15.0M Series B | Qiming Venture Partners |